A Two-Stage, Single-Blind, Dose-Escalating Study to Assess Efficacy and Safety of Resiquimod Gel Applied 5 Times Per Week for up to 12 Weeks for the Treatment of Common Warts in Adults


Phase 2
18 Years
N/A
Not Enrolling
Both
Warts

Thank you

Trial Information

A Two-Stage, Single-Blind, Dose-Escalating Study to Assess Efficacy and Safety of Resiquimod Gel Applied 5 Times Per Week for up to 12 Weeks for the Treatment of Common Warts in Adults


Inclusion Criteria:



- Diagnosis of common warts

- Two forms of birth control

Exclusion Criteria:

- Pregnant or breast feeding

- Other types of warts, ie. plantar

- Currently participating in another clinical study

- Chronic viral hepatitis B or C

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment

Outcome Measure:

Clearance of treated wart(s)

Authority:

United States: Food and Drug Administration

Study ID:

1515-RESI

NCT ID:

NCT00117871

Start Date:

October 2004

Completion Date:

Related Keywords:

  • Warts
  • Warts
  • Adults
  • Common Warts
  • Resiquimod
  • Warts

Name

Location
Minnesota Clinical Study Center Fridley, Minnesota  55432